Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy(Cancer Research UK), L. Garrison(University of Washington), Kiran Klaus Patel(La Roche College), Oscar Bertetto(Azienda Ospedaliero Universitaria San Giovanni Battista), I Bustová(Nemocnice České Budějovice), Warren Cowell(Roche (United Kingdom)), A. Malzyner(Sociedade Brasileira de Oncologia Clínica), Krzysztof Leśniewski-Kmak(Gdynia Maritime University), George Fountzilas(Aristotle University of Thessaloniki), Alfred Beham, S Jelić(Oncology Institute of Vojvodina), Jan McKendrick(Box Hill Hospital), Tim Maughan(Velindre Cancer Centre), Patrick G. Johnston(Queen's University Belfast), Werner Scheithauer(Comprehensive Cancer Center Vienna), P Dufour, J.-Y. Douillard(European Society for Medical Oncology), C.J. Twelves(University of Bradford), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Arié Figer(Ontario Institute for Cancer Research), Eduardo Díaz‐Rubio(Hospital Clínico San Carlos)
Cited by 125
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k